Okay, so Stefan, I'm going to turn it back over to you to talk about from target to treatment, what does the available evidence show for the emerging OX40-OX40 ligand inhibitors?

Let's have a look at trial data and evidence.

So both rocatindimab and emlitelemab have been studied and emlitelemab is still being studied in a huge trial program.

And this is a kind of overview on maybe the most important trials.

The STREAM-AD was the key Phase IIb study, and it included, as you can see, a withdrawal component, which was super helpful for better understanding the durability of the effects.

Then the ongoing Phase II Atlantis study will provide longer-term open-label data, and we already have some results from interim analysis.

And then the phase three program includes two monotherapy studies, the COAST-1 and COAST-2 study, and the SHORE study that evaluates mTelamab in combination with the background topical therapy.

How can the impact of AD on patients be diminished?